A5001909426- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Cancer-related Molecular Pathways
- Chronic Lymphocytic Leukemia Research
- Inflammatory Biomarkers in Disease Prognosis
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Cancer, Lipids, and Metabolism
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- PARP inhibition in cancer therapy
- Male Breast Health Studies
- Prostate Cancer Treatment and Research
- Ovarian cancer diagnosis and treatment
- Immunotherapy and Immune Responses
- Metastasis and carcinoma case studies
- Multiple and Secondary Primary Cancers
- Cancer survivorship and care
- Gastric Cancer Management and Outcomes
- Ferroptosis and cancer prognosis
- Sarcoma Diagnosis and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Immune cells in cancer
- Esophageal Cancer Research and Treatment
Dokuz Eylül University
2018-2025
Winship Cancer Institute
2023-2024
Emory Healthcare
2023-2024
Emory University
2023
There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which oncologists prefer patients with disease progression under CDKi. In addition, we show the effectiveness of systemic treatments CDKi and whether there a survival difference between hormonal (monotherapy vs. mTOR-based).A total 609 from 53 centers were included study....
Abstract Backround and purpose A low Prognostic Nutritional Index (PNI) value, which reflects immune nutrition inflammation around the tumor, is associated with an unfavorable prognosis, it was aimed to reveal its prognostic value in metastatic colorectal cancer (CRC). Methods In our retrospective cross-sectional study, patients a diagnosis of disease without active infection, between January 2010 December 2016 were included. The PNI values at time calculated according formula (10 × serum...
Accurately determining the human epidermal growth factor receptor 2 (HER2) status is crucial in identifying suitable candidates for targeted therapy gastric cancer, considering cost and potential side effects of anti-HER2 treatments. This study aimed to assess HER2 overexpression/amplification prevalence gastroesophageal cancer patients, its correlation with clinicopathological characteristics, consistency between biopsy radical specimens. We analyzed data from 667 specimens 600...
Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase as the first-line standard-of-care for patients hormone receptor-positive, HER2-negative metastatic breast cancer.
BackgroundCDK4/6 inhibitors combined with endocrine therapy have significantly improved treatment outcomes for metastatic hormone receptor-positive (HR+) breast cancer patients. However, the impact of low HER2 expression on response and progression-free survival (PFS) remains unclear.MethodsThis multicenter retrospective study included 204 HR+ patients treated a combination CDK4/6 inhibitor therapy. HER2-zero disease was detected in 138 (68%) HER2-low 66 (32%) Treatment-related...
Prognostic nutritional index (PNI), which is calculated using the albumin level reflecting status and lymphocyte count immune status, useful in showing immunological related to survival prognosis many cancers. In this study, we aimed evaluate biomarker potential effect of PNI determining metastatic castration-sensitive prostate cancer (mCSPC). This retrospective observational study included complete data 108 patients with mCPSC who were treated for at least three months between 1 January...
The only phase 3 study on the effectiveness of CDK 4-6 inhibitors in first-line treatment premenopausal patients with hormone receptor (HR) positive, HER2 negative metastatic breast cancer is MONALEESA-7 study, and data palbociclib limited. Data are also limited regarding whose dose was reduced due to neutropenia, most common side effect inhibitors. In our we aimed evaluate ribociclib reduction neutropenia progression-free survival. Our a multicenter, retrospective factors affecting survival...
Abstract Purpose The primary purpose of this study was to evaluate functional status and health-related parameters in ovarian cancer (OC) survivors compare these with healthy controls. secondary early advanced OC survivors. Methods Thirty-two ( n = 15 stage; 17 stage) no evidence/suspicion recurrence after completing adjuvant local systemic treatments for at least 12 months 32 controls were recruited functional- assessments. Participants assessed using the following methods measuring...
Aims: The aim of this study was to evaluate the effect prognostic nutritional index (PNI) on prognosis in patients with hormone receptor-positive, HER2-negative metastatic breast cancer who received CDK4/6 inhibitor + endocrine therapy. Methods: Patients receiving a were evaluated retrospectively. PNI calculated as: (10 × serum albumin [g/dl]) (total lymphocyte count [×109/l] 5). Results: In 106 patients, statistically significant survival advantage observed high-PNI group over low-PNI (mean...
(1) Background: Metastatic L-type sarcomas (liposarcoma and leiomyosarcoma) are rare have a poor prognosis. Trabectedin is an effective agent that can be used after anthracyclines. This study was designed to evaluate the real-life effectiveness safety of trabectedin. (2) Methods: A retrospective multicenter conducted on patients who were treated with trabectedin for metastatic at ten tertiary oncology centers between 2015 2023. The objective response rate (ORR), disease control (DCR), time...
Levothyroxine intoxication is a rare clinical entity which usually asymptomatic. However, severe symptoms such as respiratory failure, malignant hyperthermia, seizures, arrhythmia, and coma have been reported. In this case report, patient who ingested high dose (15 mg) levothyroxine for suicide admitted to intensive care unit was presented. There decrease in Glasgow score the follow-up. The intubated due acute failure. Gastric lavage, activated charcoal, methylprednisolone, cholestyramine...
Abstract Background Prostate cancer is a with poor host immune response and could be defined as non‐T‐cell inflamed tumor. Therefore, immunotherapy treatments not included in the treatment of prostate until recently. Inadequate antitumoral one main reasons why tumor cells multiply rapidly cause lethal results. It was shown that CD47 molecule, which secreted at high levels by leukemia cells, reduces macrophage‐mediated phagocytosis thus facilitates escape from response. The aim this study to...
Background: In this paper, it was aimed to evaluate the biomarker potential as well effect of prognostic nutritional index (PNI), which is calculated using albumin level reflecting status and lymphocyte count immune status, in determining prognosis metastatic castration-sensitive prostate cancer (mCSPC).
 
 Methods: This retrospective observational study included complete data 108 patients with mCPSC who were treated for at least three months between January 1, 2010, June 2021. The...
Objective: Prostate cancer is the second common in men Turkey. We aimed to share our single center experience on characteristics of patients with metastatic castration sensitive prostate (mCSPC) and factors affecting survival.
 Materials Methods: Between January 2007 December 2020, 280 (aged 18 years older men) who applied diagnosis carcinoma were screened this retrospective cross-sectional study. Sociodemographic clinicopathological obtained retrospectively from hospital database. The...
Aims: In this multicenter study, the authors aimed to determine real-life efficacy and safety of first-line alectinib. Materials & methods: This retrospective trial included advanced-stage, ALK-positive non-small-cell lung cancer patients who were treated with alectinib in terms ALK-tyrosine kinase inhibitors, regardless previous chemotherapy. The co-primary end points progression-free survival both for all treatment-naive population. secondary overall response rate, survival, rate CNS...